World Library  
Flag as Inappropriate
Email this Article

Cevimeline

Article Id: WHEBN0007361176
Reproduction Date:

Title: Cevimeline  
Author: World Heritage Encyclopedia
Language: English
Subject: Muscarinic agonist, SIB-1553A, TC-1827, ATC code N07, Milameline
Collection: Muscarinic Agonists, Oxathiolanes, Quinuclidines, Spiro Compounds
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Cevimeline

Cevimeline
Systematic (IUPAC) name
2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
Clinical data
Trade names Evoxac
AHFS/Drugs.com
MedlinePlus
Pregnancy
category
  • C
Legal status
  • (Prescription only)
Routes of
administration
Oral
Pharmacokinetic data
Protein binding < 20%
Identifiers
CAS Registry Number  Y
ATC code N07
PubChem CID:
DrugBank  Y
ChemSpider  Y
UNII  Y
KEGG  Y
ChEBI  N
ChEMBL  N
Chemical data
Formula C10H17NOS
Molecular mass 199.31308 g/mol
 N   

Cevimeline (Evoxac) is a parasympathomimetic and muscarinic agonist,[1] with particular effect on M1 and M3 receptors. It is used in the treatment of dry mouth and especially associated with Sjögren's syndrome.

Contents

  • Mechanism of action 1
  • Side effects 2
  • See also 3
  • References 4
  • External links 5

Mechanism of action

By activating the M3 receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.

Side effects

Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping.[2]

Contraindications include asthma and angle closure glaucoma.

See also

  • Pilocarpine - a similar parasympathomimetic medication for dry mouth (Xerostomia)
  • Bethanechol - a similar muscarinic parasympathomimetic with longer lasting effect

References

  1. ^ Ono M, Takamura E, Shinozaki K; et al. (July 2004). "Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study". Am. J. Ophthalmol. 138 (1): 6–17.  
  2. ^ [2] MedicineNet: Cevimeline. Accessed 10/12/2007

External links

  • Evoxac website
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.